Innovations in Allergy Diagnostics: Latest Developments and Breakthroughs


The Global Allergy Diagnostics Market boasts a total value of $4.8 billion in 2021 and is projected to register a growth rate of 11.1% to reach a value of $8.2 billion by 2026. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, increasing funds by organizations in allergy diagnostics are anticipated to drive growth of the global market.

Download PDF Brochure:

Market Dynamics

DRIVER: Rising environmental pollution levels

Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors causing chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas due to the higher exposure to environmental pollutants in cities (as a result of vehicular pollution and industrial activities).

As per the WHO, more than 80% of people living in urban areas are exposed to air quality levels that exceed the WHO safety limits; though this is a global trend, its effects are more severe in the urban areas of low-income countries. This is a major indicator for the growth of the allergy diagnostics market, as air pollution from motor vehicles has been indicated as one of the major risk factors responsible for allergic diseases.

OPPORTUNITY: Use of mHealth in allergy diagnosis

The use of mHealth for the diagnosis of rhinitis is currently limited, with a small number of mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.

Restraints: Premium costs associated with allergy diagnostic instruments

Several allergy diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are periodically updated by market players. As these instruments are equipped with advanced features and functionalities, they are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT). For instance, immunoassay analyzers cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. Semi-automated ELISA readers cost between USD 2,000 and USD 5,000, while fully automated analyzers cost around USD 14,000. Furthermore, maintenance and insurance, laboratory supervision, and overheads (including utilities, space, and administration) are additional expenses required to operate this equipment.

Trends: Reagent rental agreements

Reagent rental agreements are sales agreements between end users (such as hospitals and diagnostic laboratories) and allergy diagnostic product manufacturers. Under these agreements, the end user rents or purchases instruments at a subsidized rate by entering into a reagent-purchase contract with the manufacturer. This mutually beneficial agreement lowers the initial capital investment for the end user while assuring the manufacturer of purchases over a substantial time period. In some cases, analyzers are rented out to the end user at a cost-per-test rate.

Request 10% Customization:

Market Segmentation:

By Product & Service

  • Consumables
  • Instruments
  • Services

By Allergen

  • Inhaled Allergens
  • Food Allergens
  • Drug Allergens
  • Other Allergens

By Test Type

  • In Vivo Tests
  • In Vitro Tests

By End User

  • Diagnostic Laboratories
  • Hospital-based Laboratories
  • Academic Research Institutes
  • Other End Users

“North America commanded the largest share of the allergy diagnostics industry in 2021.”

Based on region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of this market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.

Key Market Players:

Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).

Report Objectives

  • To define, describe, and forecast the allergy diagnostics market based on product & service, allergen, test type, end user, and region.
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, trends, opportunities, and challenges, and COVID-19 Impact Analysis)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall allergy diagnostics market
  • To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
  • To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
  • To track and analyse competitive developments such as product launches, deals and expansions in the allergy diagnostics market.

Report Link: ( Allergy Diagnostics Market )